CompletedPhase 1

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Remternetug

Listed sites

Recruiting sites

Enrollment

139

actual

Study population

Alzheimer’s disease

Key I/E criteria

•MCI due to AD•MMSE ≥16•Study partner/caregiver required•MRI contraindications excluded

Primary endpoint

•Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID17755

Secondary IDJ1G-MC-LAKBEli Lilly and Company

NCT IDNCT04451408

Timeline

Milestones

Study first posted2020-06-30actual

Study start2020-07-07actual

Primary completion2024-11-18actual

Study completion2024-11-18actual

Last update posted2025-03-28actual

Assets

Drug assets

Remternetug

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age85 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

(Part A)

•Gradual and progressive changes in memory function reported by participants or their partners for greater than or equal to (≥) 6 months at screening, and a clinical diagnosis of mild cognitive impairment due to AD, or AD dementia, as determined by the investigator or based upon medical history

•Mini-Mental State Examination score ≥16

•Have clinical laboratory test results within normal reference range or results with acceptable deviations that are judged to be not clinically significant by the investigator

•Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available through telephone at designated times

(Part B)

•overtly healthy males or females

•have a body mass index of 18.0 to 32.0 kg/m2, inclusive

•To qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan

Exclusion criteria

(Part A)

•Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency

•Contraindication to positron emission tomography (PET)

•Have a history or presence of serious or unstable illnesses including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine, psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than (<)24 months

•Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing

•Have had significant medical history of dizziness, syncope, or vasovagal attacks within the past 3 years

•Contraindication to magnetic resonance imaging (MRI), including claustrophobia that cannot be managed with low-dose sedatives or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker

(Part B)

•have a family history of early onset AD (AD diagnosed prior to 65 years of age)

•have used or intend to use over-the-counter or prescription medication including herbal medications within 14 days prior to dosing.

•have a history or presence of significant psychiatric disorders

•have an abnormal blood pressure and/or pulse rate as determined by the investigator, or a pre-existing history of hypertension

•any clinically significant ECG or brain MRI abnormalities

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Amyloid biomarkers

1 endpoint

Secondary/protocol endpoint

Pharmacodynamics (PD): Change from Baseline in Cerebral Amyloid Plaque Level (Part A only)

Time frame:Baseline and Week 61 (part A)

change from baseline, improvement

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline through Week 61 (part A) and Week 13 (Part B)

event count, event

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3372993

Time frame:Day 1 Predose through Week 61 (part A) and Week 13 (Part B)

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve (AUC) of LY3372993

Time frame:Day 1 Predose through Week 61 (part A) and Week 13 (Part B)

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.